A Phase 1, Observer-blind, Randomised, Controlled, Single-centre Study to Evaluate the Safety, Reactogenicity, and Immune Responses to an Adjuvanted and Non-adjuvanted Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults 18 to 50 Years of Age in Europe
Latest Information Update: 29 Jan 2025
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary) ; DTaP vaccine; Typhoid vaccine Vi-polysaccharide
- Indications Typhoid
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 24 Jan 2025 Status changed from recruiting to completed.
- 03 May 2023 Status changed from not yet recruiting to recruiting.
- 21 Nov 2022 New trial record